“
TL;DR
In murine pancreatic tumor models, combined antibody blockade of IL-6 and CTLA-4 significantly inhibited tumor growth and required both CD4+ and CD8+ T cells and the CXCR3 chemokine axis.
JCI Insight · 21 authors, 9 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
In murine pancreatic tumor models, combined antibody blockade of IL-6 and CTLA-4 significantly inhibited tumor growth and required both CD4+ and CD8+ T cells and the CXCR3 chemokine axis.
The study tested whether combining antibody-mediated blockade of IL-6 and CTLA-4 could enhance antitumor immunity in murine pancreatic cancer models. Mice bearing subcutaneous MT5, orthotopic KPC-luc, and orthotopic Panc02 tumors received blocking antibodies to IL-6 and/or CTLA-4. In both tumor models, dual IL-6 and CTLA-4 blockade significantly inhibited tumor growth. The combination drove robust T cell infiltration into tumors and altered CD4+ T cell subsets, with CD4+ T cells producing more IFN-γ upon in vitro stimulation. IFN-γ stimulation of pancreatic tumor cells markedly increased production of CXCR3-specific chemokines, even in the presence of IL-6. In vivo CXCR3 blockade abolished tumor regression with combination therapy, indicating dependence on the CXCR3 axis. Depletion of either CD4+ or CD8+ T cells impaired antitumor activity, showing both subsets were required. Authors note limitations including reliance on transplantable orthotopic rather than spontaneous genetically engineered models, variability in pancreas-weight-based tumor measures, and single-time-point immune assessments. They position the work as preclinical mechanistic support for combining IL-6 and CTLA-4 blockade in pancreatic cancer.